UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2013, Volume 61, Issue 4, pp. e78 - e140
fibrinolysis | percutaneous coronary intervention | ST-elevation myocardial infarction | antiplatelets | anticoagulants | door-to-balloon | ACCF/AHA Practice Guidelines | reperfusion | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Myocardial Infarction - diagnosis | Evidence-Based Medicine - methods | Myocardial Infarction - epidemiology | Risk Assessment | United States | Humans | Diagnostic Techniques, Cardiovascular | Clinical Protocols - standards | Cardiology - standards | Medication Therapy Management - standards | Myocardial Reperfusion - methods | Patient Selection | American Heart Association | Evidence-Based Medicine - standards | Myocardial Infarction - therapy | Emergency Medical Services - organization & administration | Thrombolytic Therapy | Coronary Artery Bypass | Electrocardiography | Clinical Protocols - classification | Disease Management | Emergency Medical Services - methods | Percutaneous Coronary Intervention | Cardiology - methods | Myocardial infarction | Decision support systems | Medical personnel | Anticoagulants | Enzymes | Task forces | Medical imaging | Heart attacks | Disease | Physicians | Heart surgery | Guidelines | Disease prevention | Hospitals | Risk assessment | Coronary vessels | Quality control | Infarction | Clinical medicine | Acute coronary syndromes | Cardiology | Drug therapy
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2013, Volume 61, Issue 4, pp. 485 - 510
fibrinolysis | percutaneous coronary intervention | ST-elevation myocardial infarction | antiplatelets | anticoagulants | door-to-balloon | ACCF/AHA Practice Guidelines | reperfusion | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Myocardial Infarction - diagnosis | Evidence-Based Medicine - methods | Myocardial Infarction - epidemiology | Risk Assessment | United States | Humans | Diagnostic Techniques, Cardiovascular | Clinical Protocols - standards | Cardiology - standards | Medication Therapy Management - standards | Myocardial Reperfusion - methods | Patient Selection | American Heart Association | Evidence-Based Medicine - standards | Myocardial Infarction - therapy | Emergency Medical Services - organization & administration | Thrombolytic Therapy | Electrocardiography | Clinical Protocols - classification | Disease Management | Emergency Medical Services - methods | Percutaneous Coronary Intervention | Cardiology - methods | Myocardial infarction | Decision support systems | Medical personnel | Heart | Anticoagulants | Surgical implants | Task forces | Medical imaging | Heart attacks | Angiography | Physicians | Drug delivery | Governors | Guidelines | Hospitals | Implants | Intellectual property | Quality control | Writing | Infarction | Clinical medicine | Cardiology | Drug therapy | Veins & arteries
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2019, Volume 73, Issue 24, pp. 3168 - 3209
ACC/AHA Clinical Practice Guidelines | cardiovascular disease | patient compliance | risk assessment | lipids | drug therapy | risk reduction discussion | secondary prevention | hydroxymethylglutaryl-CoA reductase inhibitors/statins | biomarkers | proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors | diabetes mellitus | hypercholesterolemia | pharmacological | Guidelines | LDL-cholesterol | coronary artery calcium score | ezetimibe | primary prevention | cholesterol | risk treatment discussion | Risk Assessment - methods | Hypercholesterolemia - blood | Risk Reduction Behavior | United States | Cardiovascular Diseases - prevention & control | Humans | Ezetimibe - pharmacology | Biomarkers - blood | Cardiology - standards | Medication Therapy Management - standards | American Heart Association | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Proprotein Convertase 9 - antagonists & inhibitors | Hypercholesterolemia - diagnosis | Cardiovascular Diseases - psychology | Hypercholesterolemia - therapy | Anticholesteremic Agents - pharmacology | Cardiology - methods | Hypercholesterolemia - epidemiology | Calcification (ectopic) | Lipoproteins (low density) | Therapy | Calcium | Hispanic Americans | Clinical trials | Cardiovascular disease | Metabolic syndrome | Inflammatory diseases | Risk factors | Body mass index | Proliferating cell nuclear antigen | Health behavior | Drug dosages | Statins | Age | Task forces | Decision making | Coronary artery | Whites | Risk analysis | Patients | Patient compliance | Cholesterol | Disease prevention | Ethnicity | Inhibitors | Arteriosclerosis | Lifestyles | Diabetes
Journal Article
JAMA internal medicine, ISSN 2168-6106, 09/2017, Volume 177, Issue 9, pp. 1265 - 1272
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Outcome and Process Assessment, Health Care | Primary Health Care - methods | Chronic Pain - drug therapy | Humans | Middle Aged | Analgesics, Opioid - therapeutic use | Male | Electronic Prescribing - standards | Guideline Adherence - organization & administration | Medication Therapy Management - standards | Primary Health Care - standards | Medication Therapy Management - organization & administration | Long-Term Care - methods | Nursing Care - standards | Massachusetts | Adult | Female | Nursing Care - methods | Long-Term Care - organization & administration | Medical Overuse - prevention & control | Practice Guidelines as Topic
Journal Article
Kidney international, ISSN 0085-2538, 10/2015, Volume 88, Issue 4, pp. 676 - 683
kidney disease | uromodulin | hepatocyte nuclear factor-1β | genetics | mucin-1 | renin | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Predictive Value of Tests | Humans | Kidney Diseases - diagnosis | Polycystic Kidney, Autosomal Dominant - therapy | Gout - diagnosis | Nephrology - standards | Kidney Diseases - genetics | Uromodulin - classification | Uromodulin - deficiency | Polycystic Kidney, Autosomal Dominant - genetics | DNA Mutational Analysis | Hyperuricemia - therapy | Uromodulin - genetics | Genetic Predisposition to Disease | Kidney Diseases - classification | Hyperuricemia - diagnosis | Hyperuricemia - classification | Terminology as Topic | Treatment Outcome | Consensus | Hyperuricemia - genetics | Gout - therapy | Phenotype | Polycystic Kidney, Autosomal Dominant - diagnosis | Kidney Diseases - therapy | Gout - classification | Gout - genetics | Polycystic Kidney, Autosomal Dominant - classification | Mutation | Index Medicus
Journal Article